Malaga

• Clinical trial comparing Trastuzumab Deruxtecan with Trastuzumab Emtansine in high-risk HER2-positive patients with residual breast cancer f … Ended recruitment
  2023-507961-24-00 5 2021-04-19 High-Risk HER2-Positive Breast Cancer
• A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive … Ended recruitment
  2023-503568-18-00 5 2021-04-13 Early human epidermal growth factor receptor 2 (HER2) positive breast
• A study comparing current available therapies with imetelstat for the treatment of intermediate-2 or high-risk MF who are not responding to … Ended recruitment
  2023-509120-17-00 5 2021-04-12 Myelofibrosis
• A Study Evaluating The Safety, Pharmacokinetics, and Efficacy Of Crovalimab Versus Eculizumab In Participants With Paroxysmal Nocturnal Hemo … Ended recruitment
  2023-506526-37-00 5 2021-03-17 Paroxysmal Nocturnal Hemoglobinuria (PNH)
• A clinical study to assess the effectiveness and safety of LOXO-305 compared to standard of care treatment chosen by the Investigator in pat … Ended recruitment
  2023-507695-52-00 5 2021-03-05 Mantle cell lymphoma
• A Study of Osimertinib with or without Chemotherapy versus Chemotherapy alone as neoadjuvant therapy for Patients with Epidermal Growth Fact … Ended recruitment
  2022-502606-33-00 5 2021-02-26 Patients with histologically or cytologically documented non-squamous
• A Phase II clinical trial comparing the efficacy of RO7198457 versus watchful waiting in patients with ctDNA positive, resected Stage II (hi … Ended recruitment
  2023-509516-28-00 4 2021-02-22 Stage II/Stage III rectal cancer or Stage II (high risk)/Stage III col
• This is a Global Study of Neoadjuvant-Adjuvant Durvalumab or Placebo and FLOT Chemotherapy Followed by Adjuvant Durvalumab or Placebo in Pat … Ended recruitment
  2023-507338-26-00 5 2021-02-01 Histologically documented gastric or gastroesophageal junction adenoca
• Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants with Advanced NSCLC … Ended recruitment
  2023-507475-21-00 10 2021-01-18 Lung Cancer, Non-Small Cell
• Phase 3 Study of MRTX849 vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation Ended recruitment
  2023-507263-19-00 5 2020-12-23 Advanced Non-Small Cell Lung Cancer
• Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed … Ended recruitment
  2023-504959-27-00 5 2020-12-09 Participants with Limited Stage-Small Cell Lung Cancer, who have recei
• To assess the relative BA of a low-strength FDC tablet formulation of niraparib plus AA compared to niraparib and AA co-administered as sing … Ended recruitment
  2023-508150-26-00 2 2020-11-26 Metastatic castration-resistant prostate cancer (mCRPC)
• A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared with Ocrelizumab in Adult Patients with Primary Progressive Multiple Sc … Ended recruitment
  2022-502611-10-00 5 2020-11-24 Primary Progressive Multiple Sclerosis (PPMS)
• Apalutamide, Radiotherapy and LHRH Agonist in High-Risk Hormone-Sensitive Prostate Cancer Patients Assessed by PSMA-PET Ended recruitment
  2023-505852-23-00 5 2020-11-12 High risk recurrent prostate cancer previously treated with radical pr
• A Study of Atezolizumab with or without Tiragolumab in Participants with Unresectable Esophageal Squamous Cell Carcinoma whose Cancers have … Ended recruitment
  2022-502052-30-00 5 2020-10-27 Unresectable Esophageal Squamous Cell Carcinoma
• Sacituzumab Govitecan in primary HER2-negative breast cancer (SASCIA) Ended recruitment
  2023-510390-33-00 5 2020-10-23 HER2-negative breast cancer patients with high relapse risk after stan
• A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults with Relapsing Multiple Sclerosis Ended recruitment
  2023-506467-34-00 5 2020-10-20 Relapsing Multiple Sclerosis (MS)
• An open study for participants who have been on darolutamide treatment in any other Bayer study Ended recruitment
  2022-502084-38-00 5 2020-10-16 Cancer
• A Phase 3 Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment … Ended recruitment
  2023-506365-64-00 5 2020-10-16 Deleterious Germline or Somatic Homologous Recombination Repair (HRR)
• A Randomized, Open-label Phase 3 Study of Combination Amivantamab and CarboplatinPemetrexed Therapy, Compared with Carboplatin-Pemetrexed, i … Ended recruitment
  2023-506033-29-00 5 2020-10-09 EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell
• A Clinical Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients … Ended recruitment
  2023-506576-27-00 5 2020-09-30 EGFR-mutated locally advanced or metastatic Non Small Cell Lung Cancer
• A Phase 1, Open-label, Multicenter, Dose-escalation Study of CK-301 Administered Intravenously as a Single Agent to Subjects with Advanced C … Ended recruitment
  2024-517536-22-00 7 2020-09-22 Unresectable or metastatic cutaneous squamous cell carcinoma
• Clinical trial to compare efficacy and safety of standard chemotherapy versus letrozole plus abemaciclib, chosen randomly, as neoadjuvant th … Ended recruitment
  2024-514395-40-00 4 2020-08-25 High/intermediate risk hormone receptor (HR) positive/human epidermal
• Investigation of Radium-223 dichloride (Xofigo), a treatment that gives off radiation that helps kill cancer cells, compared to a treatment … Ended recruitment
  2023-505830-89-00 6 2020-08-05 metastatic castrate resistant prostate cancer (mCRPC)

Showing 721–744 of 1,048 trials